Musgrove's Tommy John recovery stalls: Padres rotation depth shields betting exposure

Joe Musgrove threw five innings and 60 pitches for Triple-A El Paso on Thursday, September 28, 2026, in what looked like another step forward in his rehab from October 2024 Tommy John surgery. The Padres right-hander then experienced arm soreness in the days following the outing—not the kind of minor residual inflammation typical in post-surgical progressions, but enough that manager Craig Stammen kept him from throwing bullpen sessions and refused to commit to a timetable for his next rehab appearance. "Joe's not recovering as quick as he would like," Stammen said, a diplomatic framing of what amounts to a stall in Musgrove's runway back to the majors.

The timeline matters here. Musgrove needed 12 days between rehab starts before the El Paso outing, a significant jump from the 4-5 day intervals typical of well-progressing recoveries. That deceleration, combined with this latest soreness episode, suggests his arm is not tracking to the aggressive return window the Padres were banking on in late July. Earlier this year, a Spring Training start triggered a setback serious enough to reset his entire timeline. This soreness isn't being characterized as that severe, but the cautious language from the front office—"everything's being reassessed on a daily basis"—signals real uncertainty about whether Musgrove pitches again before October.

Here's the stabilizing factor for San Diego's October odds: the Padres rotation is no longer built around the assumption that Musgrove returns. The Deadline trades for Robbie Ray and Casey Mize, plus the late-season improvement from Randy Vásquez and Walker Buehler, have given the rotation flesh and durability it lacked a month ago. Nick Pivetta, the other injured arm in the pipeline, threw 4 1/3 innings on Sunday with seven strikeouts, suggesting he has a better path to availability than Musgrove does. That depth insulates the Padres from betting liabilities tied to Musgrove's return.

For bettors, this is largely a fade signal for any Padres moneyline, playoff rotation-composition, or total-strikeouts prop that was priced assuming Musgrove's availability down the stretch. The market had likely already discounted his return given the public noise around his rehab, but books may still carry residual outs-per-game premiums for San Diego starting pitchers priced as if Musgrove is in the mix. Ray and Mize are now the primary vectors for Padres playoff rotation value. Musgrove's absence, rather than a fatal gap, is now something San Diego's depth can absorb.